XML 59 R36.htm IDEA: XBRL DOCUMENT v3.25.0.1
Summary of Significant Accounting Policies (Details)
 1 Months Ended 12 Months Ended
Jul. 22, 2024
USD ($)
May 25, 2023
USD ($)
Jul. 30, 2022
USD ($)
Jun. 01, 2021
USD ($)
May 31, 2021
USD ($)
Dec. 31, 2024
USD ($)
segment
Dec. 31, 2023
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue           $ 79,906,000 $ 65,421,000
Revenue recognized             1,100,000
Contract balances, account receivable           12,900,000 12,300,000
Deferred revenue           555,000 1,090,000
Remaining performance obligation           1,700,000  
Inventory write-downs           251,000 196,000
Impairment of long-lived assets           0 0
Issuance costs           212,000 509,000
Deferred offering costs           276,000 387,000
Grant period (in years)         5 years    
Research and development arrangement with federal government, total budget         $ 9,300,000    
Research and development arrangement with federal government, funding for subawards         $ 5,500,000    
Approved funding, first year       $ 800,000      
Approved funding, including subawards, first year       $ 400,000      
Approval for funding, year two $ 1,700,000 $ 3,000,000 $ 2,600,000        
Approval for funding, including subawards, year two $ 1,000,000 $ 1,500,000 $ 1,600,000        
Funding received for costs incurred           1,700,000 1,400,000
Prepaid expenses and other current assets           2,352,000 2,737,000
Advertising costs           $ 700,000 700,000
Number of operating segments | segment           1  
Number of reportable segments | segment           1  
At-the-Market Equity Offering              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Issuance costs           $ 100,000 300,000
Non-Healthcare Organizations | Accounts Receivable | Customer Concentration Risk | UNITED STATES              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Accounts receivable,with the exception of due           100,000  
Rapport              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue           $ 1,200,000 $ 400,000
Contractual support period           2 years  
Additional Funding Agreement Terms              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Compensation earned           $ 3,800,000  
Prepaid expenses and other current assets           $ 100,000  
Minimum              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Property, plant and equipment, useful life           3 years  
Maximum              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Property, plant and equipment, useful life           5 years